NGNE
Neurogene Inc.- Healthcare
- Biotechnology
- $372M market cap
Forecast run · Oct 29, 2026Upside rank 1214 of 3,186
Model Signal
ForecastQ Daily Probabilities
31.3%
80.0%
41.1%
Analyst Consensus
Recommendation2.14/5 Buy
Last price$23.55
Price target$72.00
Implied move+205.7%
Analysts7
ForecastQ Portfolios
NGNE is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.